Frontiers in Immunology | Vaccines and Molecular Therapeutics

Review

Accepted on 25 Apr 2025

Progress on the Combination Vaccines and Co-administration of Influenza Virus and SARS-CoV-2 Vaccines

in Vaccines and Molecular Therapeutics

Chengyu Hu
Chenguang Niu
Ke He
Mengyu Li
Xiaonan Gao
Qiannan Wei
Weiyang Sun
Yongkun Zhao
Yuanguo Li
Yuwei Gao

Frontiers in Immunology

doi 10.3389/fimmu.2025.1578733

353 views

Original Research

Published on 25 Apr 2025

Heterologous prime–boost Zika virus vaccination induces comprehensive humoral and cellular immunity in mouse models

in Vaccines and Molecular Therapeutics

Giuditta De Lorenzo
Rapeepat Tandavanitj
Lorena Preciado-Llanes
Ricardo Sanchez-Velazquez
Raissa Prado Rocha
Young Chan Kim
Arturo Reyes-Sandoval
Arvind H. Patel

Frontiers in Immunology

doi 10.3389/fimmu.2025.1578427

1,075 views

Original Research

Published on 24 Apr 2025

Regulatory cytokines modulate early isotype-specific response associated with COVID-19 survival

in Vaccines and Molecular Therapeutics

Sebastián Castro-Trujillo
Juanita Castro-Meneses
María Clemencia Rojas
Marcela Castro-Amaya
Giovani Lastra
Carlos F. Narváez

Frontiers in Immunology

doi 10.3389/fimmu.2025.1543626

1,435 views

Original Research

Published on 23 Apr 2025

Spatial visualization provides insight into immune modulation by an L-DBF vaccine formulation against Shigella

in Vaccines and Molecular Therapeutics

Ti Lu
Skyler T. Kramer
Mary A. York
Mst Nusrat Zahan
Debaki R. Howlader
Zackary K. Dietz
Sean K. Whittier
Nathan J. Bivens
Alexander Jurkevich
Lyndon M. Coghill

Frontiers in Immunology

doi 10.3389/fimmu.2025.1577040

1,088 views

Systematic Review

Published on 17 Apr 2025

Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis

in Vaccines and Molecular Therapeutics

Xiaopeng Wang
Li Kong
Xueou Liu
Panpan Wu
Lulu Zhang
Fangrui Ding

Frontiers in Immunology

doi 10.3389/fimmu.2025.1581970

2,816 views
1 citation

Original Research

Published on 16 Apr 2025

Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection

in Vaccines and Molecular Therapeutics

Giacomo Vezzani
Viola Viviani
Martina Audagnotto
Alessandro Rossi
Paolo Cinelli
Nicola Pacchiani
Chiara Limongi
Laura Santini
Fabiola Giusti
Sara Tomei

Frontiers in Immunology

doi 10.3389/fimmu.2025.1565862

1,584 views

Original Research

Published on 15 Apr 2025

Optimisation of the cultured ELISpot/Fluorospot technique for the selective investigation of SARS-CoV-2 reactive central memory T cells

in Vaccines and Molecular Therapeutics

Jack R. Jerome
Kirsty L. Wilson
Joshuah Fialho
Georgia Goodchild
Monica D. Prakash
Charlie McLeod
Peter C. Richmond
Vasso Apostolopoulos
Katie L. Flanagan
Magdalena Plebanski

Frontiers in Immunology

doi 10.3389/fimmu.2025.1547220

1,316 views

Original Research

Published on 11 Apr 2025

Group IIC self-splicing intron-derived novel circular RNA vaccine elicits superior immune response against RSV

in Vaccines and Molecular Therapeutics

Zeyun Sun
Lirong Lu
Lijie Liu
Ruoxu Liang
Qiqi Zhang
Zhining Liu
Jiahao An
Qian Liu
Qingxin Wu
Shuai Wei

Frontiers in Immunology

doi 10.3389/fimmu.2025.1574568

1,515 views

Original Research

Published on 11 Apr 2025

Pan-vaccinomics strategy for developing a universal multi-epitope vaccine against endocarditis-related pathogens

in Vaccines and Molecular Therapeutics

Peng Chao
Xueqin Zhang
Lei Zhang
Wei Ma
Dong Wang
Aiping Yang
Xiaoyang Chen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1524128

1,449 views

Original Research

Published on 11 Apr 2025

Protection against N. gonorrhoeae induced by OMV-based meningococcal vaccines are associated with cross-species directed humoral and cellular immune responses

in Vaccines and Molecular Therapeutics

Weiyan Zhu
Andreea Waltmann
Marguerite B. Little
Kristie L. Connolly
Kathryn A. Matthias
Keena S. Thomas
Mary C. Gray
Aleksandra E. Sikora
Alison K. Criss
Margaret C. Bash

Frontiers in Immunology

doi 10.3389/fimmu.2025.1539795

1,441 views

Original Research

Published on 10 Apr 2025

Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle

in Vaccines and Molecular Therapeutics

Jinghan Xu
Busen Wang
Zhenghao Zhao
Shipo Wu
Zhe Zhang
Shuling Liu
Nan Huo
Wanru Zheng
Yi Chen
Zhiqiang Gao

Frontiers in Immunology

doi 10.3389/fimmu.2025.1572081

1,370 views

Clinical Trial

Published on 10 Apr 2025

Shared clinical and immunologic features of mRNA vaccines: preliminary results from a comparative clinical study

in Vaccines and Molecular Therapeutics

Carlos Fierro
Nelia Sanchez-Crespo
Daniel Makrinos
Weijie Zhang
Yanbo Sun
Poonam Rohilla
Bethany Girard
Abidemi Adeniji
Anthony DiPiazza
Robert Paris

Frontiers in Immunology

doi 10.3389/fimmu.2025.1501275

3,140 views

Original Research

Published on 09 Apr 2025

Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from LDHC in lung adenocarcinoma

in Vaccines and Molecular Therapeutics

Ruifang Zhong
Xiaohong Guo
Chuncai Wu
Yangyi Guo
Yanli Kang
Jianbin You
Falin Chen
Qianshun Chen
Liangyuan Chen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1564731

1,231 views

Original Research

Published on 09 Apr 2025

Humanized mouse model reveals the immunogenicity of Hepatitis B Virus vaccine candidates produced in CRISPR/Cas9-edited Nicotiana benthamiana

in Vaccines and Molecular Therapeutics

Iuliana Caras
Irina-Elena Ionescu
Ana-Maria Pantazica
André van Eerde
Hege Steen
Inger Heldal
Sissel Haugslien
Catalin Tucureanu
Raluca-Elena Chelmus
Vlad-Constantin Tofan

Frontiers in Immunology

doi 10.3389/fimmu.2025.1479689

1,341 views

Review

Published on 08 Apr 2025

Extracellular vesicles as precision therapeutics for psychiatric conditions: targeting interactions among neuronal, glial, and immune networks

in Vaccines and Molecular Therapeutics

Ivana Kawiková
Václav Špička
James C. K. Lai
Philip W. Askenase
Li Wen
Zdeněk Kejík
Milan Jakubek
Karel Valeš
Filip Španiel

Frontiers in Immunology

doi 10.3389/fimmu.2025.1454306

1,059 views

Clinical Trial

Published on 07 Apr 2025

Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study

in Vaccines and Molecular Therapeutics

Subhash Thuluva
Ramesh V. Matur
Subbareddy Gunneri
Rammohan Reddy Mogulla
Kamal Thammireddy
Kalyan Kumar Peta
Piyush Paliwal
Niranjana S. Mahantshetti
Ramesh Kumar Banala
Prashanth Siddaiah

Frontiers in Immunology

doi 10.3389/fimmu.2025.1550227

1,811 views